Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy
- Conditions
- Interventions
- First Posted Date
- 2006-01-27
- Last Posted Date
- 2012-01-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 228
- Registration Number
- NCT00283062
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory Control
- Conditions
- Interventions
- First Posted Date
- 2006-01-27
- Last Posted Date
- 2011-01-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 390
- Registration Number
- NCT00283049
- Locations
- 🇺🇸
sanofi-aventis, US, Bridgewater, New Jersey, United States
Oxaliplatin in Unresectable Hepatocellular Carcinoma
- Conditions
- First Posted Date
- 2006-01-23
- Last Posted Date
- 2009-09-15
- Lead Sponsor
- Sanofi
- Registration Number
- NCT00280618
ALF-ONE : ALFuzosin ONcE Daily
- Conditions
- First Posted Date
- 2006-01-23
- Last Posted Date
- 2010-08-31
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 200
- Registration Number
- NCT00280605
Leflunomide in Rheumatoid Arthritis
- Conditions
- First Posted Date
- 2006-01-23
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 60
- Registration Number
- NCT00280644
- Locations
- 🇹🇷
Sanofi-Aventis, Istanbul, Turkey
Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
- First Posted Date
- 2006-01-20
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 30
- Registration Number
- NCT00280098
- Locations
- 🇨🇿
Sanofi-Aventis, Prague, Czech Republic
Riluzole in Huntington's Disease
- Conditions
- First Posted Date
- 2006-01-16
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 537
- Registration Number
- NCT00277602
LISA-study : Levothyroxin in Nodular Goiter
- Conditions
- Interventions
- First Posted Date
- 2006-01-16
- Last Posted Date
- 2009-12-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1024
- Registration Number
- NCT00277589
- Locations
- 🇩🇪
Sanofi-Aventis Administrative Office, Frankfurt, Germany
Levofloxacin, Chronic Bacterial Prostatitis
- Conditions
- First Posted Date
- 2006-01-16
- Last Posted Date
- 2007-10-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 120
- Registration Number
- NCT00277511
- Locations
- 🇩🇪
Sanofi-Aventis, Berlin, Germany
MOSAIC - Multicenter International Study of Oxaliplatin/ 5FU-LV in the Adjuvant Treatment of Colon Cancer
- Conditions
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2009-04-20
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 2246
- Registration Number
- NCT00275210
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
🇦🇺sanofi-aventis Australia & New Zealand administrative office, Macquarie Park, New South Wales, Australia